PMID: 3556193Jan 1, 1987Paper

Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris

European Journal of Clinical Pharmacology
M J BowlesE B Raftery


We have treated eleven patients with chronic stable angina pectoris with slow-release oxprenolol (160 mg and 320 mg) in a double-blind crossover study and evaluated its efficacy objectively by exercise testing between 180 and 240 min after dosing. The mean exercise time increased significantly from 6.2 min on placebo to 7.2 min and 7.3 min on oxprenolol 160 mg and 320 mg respectively. No overall beneficial effects could be demonstrated for the higher dose. A further 20 patients received slow release oxprenolol 160 mg and 10/170 mg "Oros" (osmotic release) oxprenolol in a double-blind crossover study using exercise testing and ambulatory electrocardiographic monitoring at 21-23 h after dosing. The mean exercise time increased significantly from 7.0 min on placebo to 8.3 min on slow-release oxprenolol and to 8.1 min on "Oros" oxprenolol. The effects of the 2 treatments on exercise and ambulatory heart rates were comparable. Two patients were withdrawn during the double-blind treatment period while receiving oxprenolol slow-release, one because of unstable angina and another because of throbbing headache. These findings confirm that slow-release oxprenolol is effective in treating chronic stable angina pectoris at the 160-mg dose....Continue Reading


Dec 1, 1975·Journal of Pharmaceutical Sciences·F Theeuwes
May 1, 1977·Clinical Pharmacology and Therapeutics·D G McDevittR G Shanks
Jan 1, 1979·Journal of Clinical Pharmacology·I GavrasH R Brunner
Mar 1, 1976·Clinical Pharmacology and Therapeutics·B J MatersonE C Perez-Stable
Jun 1, 1976·British Journal of Clinical Pharmacology·M J WestE B Faragher
Jan 20, 1973·British Medical Journal·U ThadaniS H Taylor
Aug 2, 1973·The New England Journal of Medicine·B Blackwell
Aug 1, 1984·International Journal of Cardiology·N S KhurmiE B Raftery
Jan 1, 1983·European Journal of Clinical Pharmacology·M W Millar-CraigE B Raftery
Jun 1, 1980·Clinical Pharmacology and Therapeutics·J FerlinzW S Aronow
Oct 1, 1980·British Heart Journal·V BalasubramanianE B Raftery

Related Concepts

Angina Pectoris
Clinical Trials
Controlled-Release Preparations
Double-Blind Method
Electrocardiographic Recorders
Cardiopulmonary Exercise Test
Pulse Rate

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.